NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.14M | 2.70M | 2.68M | 2.47M | 2.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.01M | 4.24M | 4.12M | 3.86M | 3.66M |
| Operating Income | -5.01M | -4.24M | -4.12M | -3.86M | -3.66M |
| Income Before Tax | -5.04M | -4.23M | -4.14M | -3.86M | -3.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.04 | -4.23 | -4.14 | -3.86 | -3.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.04M | -4.23M | -4.14M | -3.86M | -3.64M |
| EBIT | -5.01M | -4.24M | -4.12M | -3.86M | -3.66M |
| EBITDA | -4.95M | -4.19M | -4.07M | -3.82M | -3.63M |
| EPS Basic | -0.08 | -0.07 | -0.08 | -0.08 | -0.08 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| EPS Diluted | -0.08 | -0.07 | -0.08 | -0.08 | -0.08 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 252.63M | 229.83M | 209.84M | 191.21M | 177.53M |
| Average Diluted Shares Outstanding | 252.63M | 229.83M | 209.84M | 191.21M | 177.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |